Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Baptist Medical Center South
mi
from
Jacksonville, FL
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Baptist Medical Center South
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sands Cancer Center
mi
from
Canandaigua, NY
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sands Cancer Center
mi
from
Canandaigua, NY
Click here to add this to my saved trials
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University
mi
from
Washington,
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
Variation in Gene Expression in Neurofibromatosis Type 1
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
Variation in Gene Expression in Neurofibromatosis Type 1
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)
mi
from
Boston, MA
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Birmingham
mi
from
Birmingham, AL
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
Southern Arizona VA Health Care System, Tucson
mi
from
Tucson, AZ
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
Southern Arizona VA Health Care System, Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Long Beach
mi
from
Long Beach, CA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA San Diego Healthcare System, San Diego
mi
from
San Diego, CA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA San Diego Healthcare System, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Greater Los Angeles Healthcare System, West LA
mi
from
West Los Angeles, CA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Greater Los Angeles Healthcare System, West LA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Health Care System
mi
from
West Haven, CT
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Miami
mi
from
Miami, FL
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Augusta
mi
from
Augusta, GA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Augusta
mi
from
Augusta, GA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
Jesse Brown VAMC (WestSide Division)
mi
from
Chicago, IL
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
Jesse Brown VAMC (WestSide Division)
mi
from
Chicago, IL
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Lexington
mi
from
Lexington, KY
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Lexington
mi
from
Lexington, KY
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
Overton Brooks VA Medical Center, Shreveport
mi
from
Shreveport, LA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
Overton Brooks VA Medical Center, Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
John D. Dingell VA Medical Center, Detroit
mi
from
Detroit, MI
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
John D. Dingell VA Medical Center, Detroit
mi
from
Detroit, MI
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
G.V. (Sonny) Montgomery VA Medical Center, Jackson
mi
from
Jackson, MS
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
G.V. (Sonny) Montgomery VA Medical Center, Jackson
mi
from
Jackson, MS
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
Click here to add this to my saved trials
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated:  12/31/1969
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment
Status: Enrolling
Updated: 12/31/1969
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials